Search
You have executed a tag search on The Deal Pipeline. Below, you will find a comprehensive list of stories tagged "CVR."
4 result(s) displayed (1 - 4 of 4)
The decision tied to the approval of Folotyn cannot be appealed, but rejection does not endanger the company's $200 million merger with Spectrum Pharmaceuticals. Continue reading
Posted on June 28, 2012 4:19 PM
What can boards of directors and deal counsel do to reduce the likelihood that a proposed merger will result in litigation? Continue reading
Posted on June 12, 2012 3:03 PM
The Deal Economy 2011: Even with a structure that includes a contingent rights value, the $69 per share offer from French pharmaceutical firm Sanofi-Aventis is still too low, Whitworth said. Continue reading
Posted on January 13, 2011 10:21 AM
Movable Type search results powered by Fast Search
Thompson Hine said partners Roy Hadley Jr. and John Watkins joined its corporate transactions and securities and business litigation practice groups, respectively. For other updates launch today's Movers & shakers slideshow.
The origination partner with The Riverside Co. talks about manufacturing M&A with private equity senior editor Jon Marino. More video
